within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB16_Remdesivir;

model Remdesivir
  extends Pharmacolibrary.Drugs.ATC.J.J05AB16;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AB16</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Remdesivir is a broad-spectrum antiviral medication that inhibits viral RNA-dependent RNA polymerase. It was originally developed for the treatment of Ebola virus, but is more widely used today for the treatment of COVID-19 in hospitalized patients. Remdesivir is approved or authorized in many countries as a treatment for COVID-19.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following single intravenous dose administration.</p><h4>References</h4><ol><li><p>Brooks, KM, et al., &amp; Momper, JD (2024). Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. <i>The Journal of infectious diseases</i> 230(4) 878–888. DOI:<a href=\"https://doi.org/10.1093/infdis/jiae298\">10.1093/infdis/jiae298</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38839047/\">https://pubmed.ncbi.nlm.nih.gov/38839047</a></p></li><li><p>Walimbwa, SI, et al., &amp; Lamorde, M (2021). An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). <i>Trials</i> 22(1) 831–None. DOI:<a href=\"https://doi.org/10.1186/s13063-021-05752-1\">10.1186/s13063-021-05752-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34814933/\">https://pubmed.ncbi.nlm.nih.gov/34814933</a></p></li><li><p>Sise, ME, et al., &amp; McPhail, MJ (2024). Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 79(5) 1172–1181. DOI:<a href=\"https://doi.org/10.1093/cid/ciae333\">10.1093/cid/ciae333</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38913574/\">https://pubmed.ncbi.nlm.nih.gov/38913574</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Remdesivir;
